Boehringer Ingelheim Pharmaceuticals Inc v. InvaGen Pharmaceuticals, Inc

Court

District Court, D. Delaware (D. Del.)
Official Court Website →

Docket number

1:18-cv-01788

Cause

35:271 Patent Infringement
35 U.S.C. § 271 — Patent infringement

Nature of suit

835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

11/13/2018

1,113 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · Boehringer Ingelheim Pharmaceuticals Inc · 1176 cases
• defendant · InvaGen Pharmaceuticals Inc · 29 cases

Part of a Larger Litigation Pattern

This is one of 30 Patent - ANDA cases in our index naming InvaGen Pharmaceuticals Inc — a possible mass-tort or coordinated-litigation cluster.

• Jazz Pharmaceuticals Ireland Limited v. Invagen Pharmaceuticals, Inc
  District Court, D. New JerseyFiled 09/04/2025
• Jazz Pharmaceuticals Ireland Limited v. InvaGen Pharmaceuticals, Inc
  District Court, E.D. New YorkFiled 09/12/2024
• Boehringer Ingelheim Pharmaceuticals Inc v. InvaGen Pharmaceuticals, Inc
  District Court, D. DelawareFiled 08/09/2019
• Genentech, Inc v. InvaGen Pharmaceuticals, Inc
  District Court, D. DelawareFiled 02/01/2019
• Sumitomo Dainippon Pharma Co., Ltd v. InvaGen Pharmaceuticals Inc
  District Court, E.D. New YorkFiled 03/08/2018
• Mitsubishi Tanabe Pharma Corporation v. Invagen Pharmaceuticals, Inc
  District Court, D. New JerseyFiled 08/23/2017

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is Boehringer Ingelheim Pharmaceuticals Inc v. InvaGen Pharmaceuticals, Inc?

Boehringer Ingelheim Pharmaceuticals Inc v. InvaGen Pharmaceuticals, Inc is a federal patent - anda lawsuit filed on 11/13/2018 in the District Court, D. Delaware. The case is currently open in the federal court system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, D. Delaware, docket number 1:18-cv-01788.

When was the case filed?

Boehringer Ingelheim Pharmaceuticals Inc v. InvaGen Pharmaceuticals, Inc was filed on 11/13/2018. The case is currently open.

What law is the case brought under?

The docket lists the cause as 35 U.S.C. § 271 — Patent infringement.